$21.85
6.53%
Nasdaq, Thu, Sep 24 2026.
ISIN
US2826442020
Symbol
EKSO

Ekso Bionics Holdings, Inc. Stock price

$21.85
-0.72 3.19% 1M
+11.35 108.10% 6M
+13.21 152.89% YTD
+17.19 368.88% 1Y
+11.80 117.41% 3Y
-48.56 68.97% 5Y
-788.15 97.30% 10Y
-3,679.40 99.41% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
+1.34 6.53%

Is Ekso Bionics Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$2.9m
Cash
$1.2m
Shares outstanding
3.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
44.9%
Return on Equity
-132.1%
ROCE
-114.6%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$12.8m | $23.2m
EBITDA
$-11.6m
EBIT
$-13.1m
Net Income
$-11.9m
Free Cash Flow
$-12.0m
Growth (TTM | estimate)
Revenue
-28.6% | 81.2%
EBITDA
-30.7%
EBIT
-25.7%
Net Income
-5.2%
Free Cash Flow
-21.4%
Margin
Gross
53.5%
EBITDA
-90.4%
EBIT
-102.7%
Net
-93.1%
Free Cash Flow
-93.7%
More
EPS
$-3.7
FCF per Share
$-3.4
Short interest
7.3%
Employees
53
Rev per Employee
$240.0k

Ekso Bionics Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Ekso Bionics Holdings, Inc.

Dec '25
+/-
%
13 13
29% 29%
100%
- Direct Costs 5.95 5.95
29% 29%
46%
6.85 6.85
28% 28%
54%
- Selling and Administrative Expenses 17 17
5% 5%
133%
- Research and Development Expense 3.03 3.03
22% 22%
24%
-12 -12
31% 31%
-90%
- Depreciation and Amortization 1.57 1.57
2% 2%
12%
EBIT (Operating Income) EBIT -13 -13
26% 26%
-103%
Net Profit -12 -12
5% 5%
-93%

In millions USD.

Don't miss a Thing! We will send you all news about Ekso Bionics Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ekso Bionics Holdings, Inc. Stock News

Neutral
GlobeNewsWire
●
5 months ago
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors.

Company Profile

Ekso Bionics Holdings, Inc. engages in the design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following business segments: EksoHealth, EksoWorks, and Other. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.

Head office United States
CEO Mr. Davis
Employees 53
Founded 2012
Website eksobionics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today